Anhui H7N9

Hemagglutinin-Influenza A Virus H7N9 Anhui 2013 Recombinant
Cat. No.
BT25184
Source

Sf9, Baculovirus cells.

Synonyms

Hemagglutinin, Influenza A virus (A/Anhui/1-BALF_RG45/2013(H7N9) hemagglutinin, HA, Hemagglutinin HA1 chain, Hemagglutinin HA2 chain

Appearance
Sterile Filtered colorless solution.
Purity

Greater than 95.0% as determined by SDS-PAGE.

Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock

Description

Anhui H7N9 produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 330 amino acids (19-339 aa) and having a molecular mass of 36 kDa.
Anhui H7N9 is fused to a 6 amino acid His tag at C-terminus and purified by proprietary chromatographic techniques.

Product Specs

Introduction
Hemagglutinin-Influenza A Virus H7N9 Anhui 2013 (Anhui H7N9) is part of the influenza virus hemagglutinin family. Antigenic glycoprotein H7N9 Anhui is responsible for binding the virus to the infected cell. An H7N9 virus was first reported to have infected humans in March 2013, in China. Although the risk is low, the H7N9 virus has the greatest potential to cause a pandemic compared to other influenza A viruses. This is because, like other type A viruses, it is not easily transmitted between people in its current form.
Description
Produced in Sf9 Baculovirus cells, Anhui H7N9 is a single, glycosylated polypeptide chain containing 330 amino acids (19-339 aa) and having a molecular mass of 36 kDa. Anhui H7N9 is fused to a 6 amino acid His tag at the C-terminus and purified by proprietary chromatographic techniques.
Physical Appearance
Sterile Filtered colorless solution.
Formulation
The Anhui H7N9 solution (1mg/ml) contains 10% Glycerol and Phosphate-Buffered Saline (pH 7.4).
Stability
Store at 4°C if the entire vial will be used within 2-4 weeks. Store frozen at -20°C for longer periods. For long-term storage, adding a carrier protein (0.1% HSA or BSA) is recommended. Avoid multiple freeze-thaw cycles.
Purity
Greater than 95.0% as determined by SDS-PAGE.
Synonyms

Hemagglutinin, Influenza A virus (A/Anhui/1-BALF_RG45/2013(H7N9) hemagglutinin, HA, Hemagglutinin HA1 chain, Hemagglutinin HA2 chain

Source

Sf9, Baculovirus cells.

Amino Acid Sequence

ADLDKICLGH HAVSNGTKVN TLTERGVEVV NATETVERTN IPRICSKGKR TVDLGQCGLL GTITGPPQCD QFLEFSADLI IERREGSDVC YPGKFVNEEA LRQILRESGG IDKEAMGFTY SGIRTNGATS ACRRSGSSFY AEMKWLLSNT DNAAFPQMTK SYKNTRKSPA LIVWGIHHSV STAEQTKLYG SGNKLVTVGS SNYQQSFVPS PGARPQVNGL SGRIDFHWLM LNPNDTVTFS FNGAFIAPDR ASFLRGKSMG IQSGVQVDAN CEGDCYHSGG TIISNLPFQN IDSRAVGKCP RYVKQRSLLL ATGMKNVPEI PKGRHHHHHH

Product Science Overview

Introduction

Hemagglutinin (HA) is a surface glycoprotein found on the influenza virus, playing a crucial role in the virus’s ability to infect host cells. The H7N9 strain of the influenza A virus, particularly the Anhui 2013 variant, has garnered significant attention due to its potential to cause severe respiratory illness in humans.

Origin and Evolution

The H7N9 influenza virus was first identified in humans in China in 2013. The Anhui 2013 strain, specifically, is a reassortant virus, meaning it contains genetic material from multiple influenza viruses. Phylogenetic analysis suggests that the HA gene of this virus is derived from an H7N3 virus found in Eurasian wild birds, while the neuraminidase (NA) gene comes from either H11N9 or H2N9 viruses from wild birds. The internal genes (PB2, PB1, PA, NP, M, and NS) are from H9N2 viruses in poultry in China .

Structure and Function

Hemagglutinin is responsible for binding the virus to the host cell’s surface receptors, facilitating viral entry. The HA protein of the H7N9 virus has undergone several mutations that enhance its ability to bind to human cell receptors, increasing its virulence. Notably, mutations such as A135T and N171S in the HA protein have been identified in the Anhui 2013 strain .

Antigenic Drift

Antigenic drift refers to the gradual accumulation of mutations in the HA protein, leading to changes in its antigenic properties. This process allows the virus to evade the host’s immune response. Studies have shown that the H7N9 virus has undergone significant antigenic drift since its emergence, with mutations like A143V, A143T, and R148K reducing the virus’s susceptibility to neutralization by antisera .

Immunogenicity and Vaccine Development

The HA protein of the H7N9 virus, particularly the Anhui 2013 strain, has been found to elicit weak immune responses. This low immunogenicity may be due to regulatory T cell (Treg)-stimulating epitopes in the HA protein. Efforts to develop vaccines against H7N9 have focused on engineering the HA protein to improve its immunogenicity .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.